ICU Medical Q2 Earnings Call Highlights

ICU Medical Q2 Earnings Call Highlights

Strong second-quarter performance: Revenue reached $548 million, with organic growth of 6%; adjusted EBITDA rose 10% to $110 million and adjusted EPS increased 13% to $2.37. Growth in consumables and infusion systems offset weakness in Vital Care and the IV Solutions deconsolidation. Full-year outlook raised: ICU Medical increased adjusted EBITDA guidance to $415 million–$435 million and adjusted EPS guidance to $8.60–$9.00, while maintaining its approximately $150 million free-cash-flow target and aiming for roughly 2.0x leverage by year-end. Vital Care stabilizing amid ongoing headwinds: The segment declined organically but improved sequentially, and management expects relative stability for the rest of 2026. The company continues to face tariff and currency pressures while advancing its Medfusion 5000 pump submission and supporting Otsuka’s planned $500 million IV Solutions production investment.

ICU Medical NASDAQ: ICUI reported second-quarter revenue of $548 million, up 6% organically and 1% on a reported basis, as growth in its consumables and infusion systems businesses helped offset continued pressure in Vital Care and the effects of the IV Solutions joint venture deconsolidation. Adjusted EBITDA rose 10% year over year to $110 million, while adjusted diluted earnings per share increased 13% to $2.37.

The company raised and narrowed its full-year adjusted EBITDA guidance to $415 million to $435 million, from $400 million to $430 million, and lifted adjusted EPS guidance to $8.60 to $9.00, from $7.75 to $8.45.

Consumables and Infusion Systems Set Revenue Records

CEO and Chairman Vivek Jain said consumables revenue reached a record in absolute sales, increasing 6% reported and 5% organically. Growth was balanced across the segment’s four product families, all of which improved from a year earlier. Management continues to expect mid-single-digit growth in consumables for the full year. Infusion systems revenue increased 13% reported and 12% organically, driven by a record quarter in pumps. Dedicated sets tracked the favorable consumables trend, while capital sales were also strong. However, declines in OEM revenue are expected to remain a headwind to growth for the rest of the year. Jain said some installations occurred earlier than expected during the second quarter and will shift out of later periods. He reiterated that the company expects infusion systems organic growth to continue at or above 6% in the near term. During the question-and-answer session, Jain said the pump results primarily reflected installation of competitive wins secured last year or earlier in 2026, rather than a broad acceleration in replacement activity. Some sales were upgrades for existing customers, but he said the majority were competitive wins. The company does not expect customers to accelerate upgrades ahead of their normal capital cycles. Jain also said pricing for the company’s Duo and Solo large-volume pumps has held in the market, which he attributed to the products’ value proposition.

Vital Care Stabilizes After Product Actions

Vital Care revenue declined 4% organically and 32% on a reported basis. The reported decline reflected the mid-2025 formation of Otsuka ICU Medical LLC and the resulting deconsolidation of the IV Solutions business from ICU Medical’s income statement. Management said Vital Care improved sequentially and expects the business to be relatively stable through the remainder of 2026, though down slightly for the full year due to first-quarter performance. Jain said much of the SKU rationalization work in the business was completed earlier in the year, contributing to the sharp first-quarter decline. He added that the company...